Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Aug 2011

Shah Samir R, Patel Keyur, Marcellin Patrick, Foster Graham R, Manns Michael, Kottilil Shyam, Healey Letha, Pulkstenis Erik, Subramanian G Mani, McHutchison John G, Sulkowski Mark S, Zeuzem Stefan, Nelson David R

Abstract excerpt

BACKGROUND & AIMS: It is recommended that patients with chronic hepatitis C virus (HCV) genotype 3 infections receive 24 weeks of treatment. A rapid virologic response (RVR; at week 4) predicts a sustained virologic response (SVR), although not all patients with an RVR achieve an SVR. We explored...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to gamma-Glutamyltransferase

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Liver Cirrhosis

Share to Recurrence

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 21640198
DOI: 10.1016/j.cgh.2011.04.029
PMCID: PMC3155986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21640198-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.PMID 21640198Read ↗

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.Semantic proximity Read ↗

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.Semantic proximity Read ↗

Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.Semantic proximity Read ↗

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?Semantic proximity Read ↗

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.Semantic proximity Read ↗

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.Semantic proximity Read ↗

Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.Semantic proximity Read ↗

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.Semantic proximity Read ↗

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.Semantic proximity Read ↗

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.Semantic proximity Read ↗

Identifying HCV genotype 1 patients at risk of relapse.Semantic proximity Read ↗

Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.